Literature DB >> 28167658

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Dario Campana1, Ching-Hon Pui2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28167658      PMCID： PMC5383866          DOI： 10.1182/blood-2016-12-725804

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  42 in total

Review 1.  The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement.

Authors:  Denise M Oliansky; Bruce Camitta; Paul Gaynon; Michael L Nieder; Susan K Parsons; Michael A Pulsipher; Hildy Dillon; Thomas A Ratko; Donna Wall; Philip L McCarthy; Theresa Hahn
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-07       Impact factor: 5.742

2.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Authors:  Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

Review 3.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Authors:  Jae H Park; Mark B Geyer; Renier J Brentjens
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

4.  Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Authors:  Ching-Hon Pui; Deqing Pei; Elaine Coustan-Smith; Sima Jeha; Cheng Cheng; W Paul Bowman; John T Sandlund; Raul C Ribeiro; Jeffrey E Rubnitz; Hiroto Inaba; Deepa Bhojwani; Tanja A Gruber; Wing H Leung; James R Downing; William E Evans; Mary V Relling; Dario Campana
Journal:  Lancet Oncol       Date:  2015-03-20       Impact factor: 41.316

5.  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.

Authors:  Patricia Stow; Laura Key; Xiaohua Chen; Qiulu Pan; Geoffrey A Neale; Elaine Coustan-Smith; Charles G Mullighan; Yinmei Zhou; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2010-03-19       Impact factor: 22.113

6.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 8.  Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.

Authors:  Ching-Hon Pui; Jun J Yang; Stephen P Hunger; Rob Pieters; Martin Schrappe; Andrea Biondi; Ajay Vora; André Baruchel; Lewis B Silverman; Kjeld Schmiegelow; Gabriele Escherich; Keizo Horibe; Yves C M Benoit; Shai Izraeli; Allen Eng Juh Yeoh; Der-Cherng Liang; James R Downing; William E Evans; Mary V Relling; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.

Authors:  Katharine Patrick; Rachel Wade; Nick Goulden; Chris Mitchell; Anthony V Moorman; Clare Rowntree; Sarah Jenkinson; Rachael Hough; Ajay Vora
Journal:  Br J Haematol       Date:  2014-04-08       Impact factor: 6.998

10.  Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Authors:  C-H Pui; D Pei; S C Raimondi; E Coustan-Smith; S Jeha; C Cheng; W P Bowman; J T Sandlund; R C Ribeiro; J E Rubnitz; H Inaba; T A Gruber; W H Leung; J J Yang; J R Downing; W E Evans; M V Relling; D Campana
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
View more
  39 in total

Review 1.  Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia.

Authors:  Emily B Heikamp; Ching-Hon Pui
Journal:  J Pediatr       Date:  2018-09-10       Impact factor: 4.406

2.  Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia.

Authors:  Amy K Keating; Nathan Gossai; Christine L Phillips; Kelly Maloney; Kristen Campbell; Andrew Doan; Deepa Bhojwani; Michael J Burke; Michael R Verneris
Journal:  Blood Adv       Date:  2019-07-09

3.  Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Authors:  A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

4.  Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Authors:  Yi Tian Png; Natasha Vinanica; Takahiro Kamiya; Noriko Shimasaki; Elaine Coustan-Smith; Dario Campana
Journal:  Blood Adv       Date:  2017-11-21

5.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

Review 6.  Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.

Authors:  Franklin Fuda; Weina Chen
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

7.  [Clinical characteristics and prognostic analysis of pediatric pro-B cell acute lymphoblastic leukemia].

Authors:  Yu-Juan Xue; Ai-Dong Lu; Yu Wang; Yue-Ping Jia; Ying-Xi Zuo; Le-Ping Zhang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-12

8.  Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.

Authors:  Senthil Velan Bhoopalan; Shane J Cross; John C Panetta; Brandon M Triplett
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-10       Impact factor: 3.333

9.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL.

Authors:  Brent Wood; David Wu; Beryl Crossley; Yunfeng Dai; David Williamson; Charles Gawad; Michael J Borowitz; Meenakshi Devidas; Kelly W Maloney; Eric Larsen; Naomi Winick; Elizabeth Raetz; William L Carroll; Stephen P Hunger; Mignon L Loh; Harlan Robins; Ilan Kirsch
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

10.  A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters.

Authors:  Michael Keeney; Brent L Wood; Benjamin D Hedley; Joseph A DiGiuseppe; Maryalice Stetler-Stevenson; Elisabeth Paietta; Gerard Lozanski; Adam C Seegmiller; Bruce W Greig; Aaron C Shaver; Lata Mukundan; Howard R Higley; Caroline C Sigman; Gary Kelloff; J Milburn Jessup; Michael J Borowitz
Journal:  Cytometry B Clin Cytom       Date:  2017-05-05       Impact factor: 3.058
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.